Post by icemandios on Apr 29, 2021 13:04:29 GMT
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings
PR Newswire
MARLBOROUGH, Mass. , April 29, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held on May 11 - May 14, 2021 , and the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held on June 4 - 8, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: 24th Annual Meeting of the ASGCT
Poster Title: INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: 431
Date/Time: 8:00 AM - 10:00 AM on Tuesday, May 11, 2021
Event: The 2021 ASCO Annual Meeting
Poster Title: INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: e14537
Date: Friday, June 4, 2021
Archived versions of the Phio presentations will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
PR Newswire
MARLBOROUGH, Mass. , April 29, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced new data to be presented at the upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which is being held on May 11 - May 14, 2021 , and the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held on June 4 - 8, 2021 .
Logo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows:
Event: 24th Annual Meeting of the ASGCT
Poster Title: INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: 431
Date/Time: 8:00 AM - 10:00 AM on Tuesday, May 11, 2021
Event: The 2021 ASCO Annual Meeting
Poster Title: INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice
Authors: Benjamin Cuiffo, et al.
Abstract Number: e14537
Date: Friday, June 4, 2021
Archived versions of the Phio presentations will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .